Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 1 1

Status

Recruiting 2Completed 1Available 1

Sponsor Class

INDUSTRY 4

Study Type

Interventional 2Observational 1Expanded_access 1

Sponsor

Cancer Type

Tumor-Agnostic 4Gastrointestinal 3

Conditions

Adenocarcinoma 4Neoplasms 2

Interventions

Oxaliplatin 14Gemcitabine 13Fluorouracil 11Leucovorin 9Capecitabine 9pembrolizumab 7Docetaxel 7Irinotecan 6Paclitaxel 5zolbetuximab 4regorafenib 4Trastuzumab 4Radiotherapy 4Pemetrexed 4S 1 (combination) 3Ramucirumab 3Nivolumab 3Drug Therapy 3Cisplatin 3Bevacizumab 3vandetanib 2tislelizumab 2sargramostim 2lenvatinib 2icotinib 2camrelizumab 2bemarituzumab 2apatinib 2Phlebotomy 2Esophagectomy 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Adenocarcinoma × zolbetuximab × Tumor-Agnostic × Clear all
NCT06901531 2026-04-29

LUCERNA

Astellas Pharma Inc

Phase 3 Recruiting
500 enrolled
Tumor-Agnostic

Adenocarcinoma, Neoplasms

NCT06902545 2026-03-11

A Study to Observe the Safety of VYLOY (Zolbetuximab) in People in South Korea With Gastric or Gastroesophageal Junction Cancer.

Astellas Pharma Inc

Recruiting
377 enrolled
Tumor-Agnostic

Adenocarcinoma, Neoplasms

NCT06048081 2025-09-10

Early Access Program for Zolbetuximab

Astellas Pharma Inc

Available
Tumor-Agnostic

Adenocarcinoma

NCT04086758 2024-11-20

A Pharmacokinetic Study of Zolbetuximab (IMAB362) in Chinese Subjects With Locally Advanced Unresectable or Metastatic Gastric or Gastro-esophageal Junction (GEJ) Adenocarcinoma

Astellas Pharma Inc

Phase 1 Completed
12 enrolled
Tumor-Agnostic

Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡